This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Varian Slips on Outlook

Varian Medical Systems (VAR - Get Report) sank 3% late Wednesday after offering soft second-quarter guidance.

The news came as the company reported strong quarterly earnings and raised its full-year guidance, citing strong demand for its medical equipment.

The Palo Alto, Calif.-based manufacturer earned $50 million, or 37 cents a share, in its fiscal first quarter, up from of $41 million, or 30 cents a share, a year ago. Analysts surveyed by Thomson First Call were expecting Varian to earn 36 cents a share.

Revenue reached $388 million for the quarter, up 16% from the year-ago period. Revenue from its oncology systems totaled $316 million, up 15% from a year ago. X-ray product revenue was $62 million, 19% higher than the year-ago quarter. Analysts were expecting overall revenue of $382.15 million.

"This quarter was highlighted by strong growth in net orders for image-guided radiotherapy and stereotactic radiosurgery products in North America and for flat-panel digital image detectors for filmless X-rays," said Timothy Guertin, president and CEO of Varian Medical Systems, in a press release after the close of trading Wednesday.

For the full year, Varian expects revenue to grow 13%, with 7% to 9% growth in its second quarter. The company's 2007 earnings should be between $1.89 and $1.91 a share, with second quarter earnings at around 46 cents a share, excluding the impact of Varian's intended acquisition of Accel Instruments.

Analysts were looking for 48 cents for the quarter and $1.87 for the year.

Shares dropped $1.70 late Wednesday to $48.44.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs